Active surveillance for favorable risk prostate cancer: Rationale, results, and vis a vis focal therapy role

Minerva Urologica e Nefrologica

Volumn 63, Issue 2, 2011, Pages 145-153

  Klotz, L ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Prostatic diseases; Prostatic neoplasms; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; CANCER SURVIVAL; CANCER THERAPY; CRYOABLATION; DIAGNOSTIC IMAGING; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; PATIENT MONITORING; PATIENT SELECTION; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WATCHFUL WAITING;

HUMANS; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 79961012450     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664-9. (Pubitemid 34240696)
2. Thompson I, Thrasher JB, Aus G, Burnett AL, CanbyHagino ED, Cookson MS et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106.
3. National Comprehensive Cancer Network (NCCN) Guidelines. [cited 2011 May 17]. Available at: www.nccn.org.
4. Nguyen CT, Jones JS. Focal therapy in the management of localized prostate cancer. BJU Int 2011 [In press].
5. Klotz, L. Active surveillance for favorable-risk prostate cancer: who, how and why?. Nat Clin Pract Oncol 2007;4:692.
6. Konety, BR, Bird, VY, Deorah, S, Dahmoush, L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005;174:1785.
7. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215.
8. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005;97:1132-7. (Pubitemid 41511212)
9. Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267:2191-6.
10. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101. (Pubitemid 40617061)
11. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
12. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144.
13. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010;102:950-8.
14. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185:869-75.
15. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74. (Pubitemid 24037911)
16. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153:1543.
17. Noguchi M, Stanley TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001;166:104-9. (Pubitemid 32565354)
18. Dall'Era MA, Cooperberg MR, Chan JM, Davies HJ, Albertsen PC, Klotz LH et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008;112:1650-9. (Pubitemid 351536825)
19. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994;44:862-7.
20. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407-11. (Pubitemid 29483051)
21. Augustin H, Hammerer PG, Graefen M, Erbersdobler A, Blonski J, Palisaar J et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 2003;43:455-60.
22. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004;64:544.
23. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. Cancer 2004;101:2001-5. (Pubitemid 39425375)
24. Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA. The Epstein Criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 2010;58:90-5.
25. Klotz L. Active surveillance for prostate cancer: trials and tribulations. World J Urol 2008;26:437.
26. erg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007;177:107-12.
27. Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008;112:69-74.
28. Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schröder FH. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer 2007;110:2218-21. (Pubitemid 350100743)
29. Choo R, Do V, Sugar L, Klotz L, Bahk E, Hong E et al. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer. Can J Urol 2004;11:2118.
30. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004;171:1520.
31. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
32. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010;183:520-7.
33. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA et al. Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer. Radiology 2011;259:453-61
34. Shappley WV 3rd, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27:4980.
35. Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009;182:2274.
36. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS et al. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int 2009;103:1472.
37. van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297.
38. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359.
39. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664-70. (Pubitemid 351969209)
40. tami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170-4.
41. Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson J; National Prostate Cancer Register. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol 2008;180:2423-9.
42. United States National Institutes of Health, Clinical trials database. [cited 2011 May 17]. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00632983?term=Prostate+Testing+for+Cancer+and+Treatment&rank=1).
43. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, Duchane J et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007;178:826-31.
44. Bailey DE, Mishel MH, Belyea M, Stewart JL, Mohler J. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs 2004;27:339-46. (Pubitemid 39346525)
45. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-8.
46. Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664-9.
47. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G et al. Prostate cancer metastases have a monoclonal origin. Nat Med 2009;15:559-65.